PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

PTC Therapeutics ( (PTCT) ) has released its Q3 earnings. Here is a breakdown of the information PTC Therapeutics presented to its investors.

PTC Therapeutics (PTCT) reported $196.79 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 0.1%. EPS of -$1.39 for the same period compares to -$1.76 a ...

The biopharmaceutical company posted revenue of $196.8 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $173.5 million. PTC Therapeutics expects full-year ...

When the colder months approach, having a reliable and efficient heating source becomes a priority. The Snug Heater has emerged as a popular choice among consumers looking to stay warm without ...

Berenberg downgraded PTC ( PTC, Financials) to hold from buy on Friday, citing a lack of stabilization in key markets that have continued to experience macroeconomic challenges, particularly aerospace ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Configit, the global leader in Configuration Lifecycle Management (CLM), today announced a strategic partnership and joint go-to-market strategy with PTC, a global software company that provides ...

WARREN, N.J., Oct. 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New ...

Mizuho has recently reduced PTC Inc (PTC) stock to Neutral rating, as announced on June 4, 2024, according to Finviz. Earlier, on January 4, 2024, JP Morgan had raised the stock from a Neutral to ...